Laurus Labs Limited is a research-driven pharmaceutical and biotechnology company founded in 2005 by Dr. Satyanarayana Chava, who remains its Founder and Chief Executive Officer. Its corporate office is in Jubilee Hills, Hyderabad, and its registered office is at Laurus Enclave in Parawada mandal, Anakapalli district, Andhra Pradesh. The shares trade on the NSE as LAURUSLABS and on the BSE under 540222. The company holds a leading position in active pharmaceutical ingredients and finished dosage forms for anti-retroviral, oncology, cardiovascular and gastro therapeutics.
Laurus reports two divisions. CDMO serves innovator companies from early development through commercial supply, covering small molecules and, through Laurus Bio, large molecules and enzymes. Affordable Medicines covers generic APIs and finished dosage forms, with anti-retrovirals still a large share. In the first half of FY27, CDMO revenue rose 71% to ₹1,774 crore and Affordable Medicines grew 13% to ₹2,459 crore, taking total revenue to ₹4,233 crore at a 33.2% EBITDA margin. The group also supplies animal-health APIs, intermediates, crop-science and specialty ingredients for nutrition and cosmetics, and it has invested in cell and gene therapy through a minority stake in ImmunoACT.
The company set up its R&D operation in 2006 and its first plant, Unit 1 at Visakhapatnam, in 2007. It filed its first Drug Master File and supplied its first product to the US in 2008. Unit 1 won USFDA, TGA and UK MHRA approval in 2010, and the first finished-dosage product, Tenofovir, launched in the US, Canada and emerging markets in 2018. Later steps include buying Aspen's South African subsidiary in 2020, taking 72.55% of Richcore Life Sciences (now Laurus Bio) in 2021, a joint venture with KRKA in January 2024 and a new R&D centre at IKP Knowledge Park, Genome Valley, opened in September 2024. In October 2026 Laurus agreed to take 60% of Galenvs Sciences, a Montréal oligonucleotide and magnetic-nanoparticle specialist.
Manufacturing runs across 15 sites approved by regulators including the USFDA, WHO and EMA, including facilities near Visakhapatnam at Parawada and the APSEZ at Atchutapuram. The FY26 annual report lists 8,200 KL of reactor volume, 12 billion units of formulation capacity and 240 KL of fermentation capacity. In 2026 the company opened its first commercial-scale peptide plant in Vizag with more than 16,000 litres of solid-phase peptide synthesis capacity, and its LB-4 fermentation unit of over 400 kL is due to be commissioned in the third quarter of FY27. Six R&D sites spent ₹282 crore in FY26. Laurus has filed 600+ patents and 92 DMFs, has 96 finished-dosage products filed in developed markets and runs 125+ active CDMO projects.
Headcount reached 8,126 on 31 March 2026, up from 7,042 a year earlier, after more than 1,700 hires. About 3,134 of these employees are scientists and quality staff. Attrition fell to 10.3% from 17%, and millennials make up 88% of the permanent workforce. Women were 9% of employees in FY26, and the company ran walk-in drives in Goa, Hyderabad, Ahmedabad and Chennai alongside campus hiring. Its 2025 DARPAN engagement survey reached 6,553 employees with a 96% response rate and a Trust Index of 83, and Laurus has been certified a Great Place to Work for six consecutive years.